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Background: The relationship between stress, symptoms of inflammatory bowel disease 
(IBD), and depression has not previously been considered using the theory of subjective 
wellbeing (SWB) homeostasis as a conceptual framework. It is proposed that mindfulness, as 
a mechanism of down-regulating challenging emotion, can aid in the restoration of mood 
homeostasis and reduce symptoms of both psychological and physiological stress. The study 
aims to identify whether individuals with Crohn’s disease (CD) and co-occurring psychological 
depression or stress are experiencing the defeat of SWB homeostasis. Further, the study aims 
to test whether a Mindfulness Based Stress Reduction (MBSR) intervention can restore 
homeostasis. The study would also identify whether this restoration of homeostasis is 
associated with a reduction in disease symptomatology.  
 
Methods/Design: An exploratory randomised control trial with 40 participants recruited from 
public health gastroenterology patients and randomly allocated to an 8-week MBSR program 
or wait-list control. Measures of SWB, depression, stress, and C-reactive protein (CRP) levels 
will be collected prior to and after the intervention. Individual HPMood set points will be 
determined from affect data collected over 7 days through momentary sampling techniques 
prior to the commencement of the intervention. Measures will be repeated at 6-month follow-
up. Following this, the wait-list group will be offered the same 8-week MBSR. Hypotheses 
will be tested using mixed ANOVA and clinical significance tests. 
 
Discussion: This study will be an important contributor to knowledge about psychological 
vulnerability and resilience for people with CD and will provide initial evidence that could 
contribute to the development of a larger future trial. 
 
Trial registration: ACTRN12618002009291 
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1.  Background 
1.1  Crohn’s disease and psychological symptoms 
Crohn’s disease (CD) is a type of inflammatory bowel disease (IBD), with relapsing 
symptoms including abdominal pain, change in bowel habit, weight loss and rectal bleeding 
(Abautret-Daly et al., 2018). CD is increasing in incidence and prevalence across ethnic groups 
and geographies (Baumgart & Sandborn, 2012). A number of studies have found relationships 
between stress and disease outcomes (Bernstein et al., 2010; Cámara et al., 2009; Duffy et al., 
1991), and  there appears to be a growing consensus that stress plays a role in IBD activity 
(Knowles & Mikocka-Walus, 2015; Triantafillidis et al., 2013). Other psychological conditions 
are also strongly associated with IBD. A longitudinal analysis of more than 2000 patients (56% 
with CD) over nine years found a significant association between symptoms of depression and 
anxiety and disease recurrence (Fairbrass et al., 2021; Mikocka-Walus, Pittet, et al., 2016). A 
systematic literature review confirmed the higher prevalence of anxiety and depression 
amongst patients with IBD than healthy controls, with the prevalence rising for those with 
active disease symptoms (Barberio et al., 2021; Mikocka-Walus, Knowles, et al., 2016).  
The high levels of co-morbidity have led to an increase in research into appropriate 
psychological treatments for patients with IBD (Gracie et al., 2017; Triantafillidis et al., 2013; 
von Wietersheim & Kessler, 2006). Longitudinal studies have provided evidence that 
psychological co-morbidity negatively impacts disease course (Fairbrass et al., 2021) and there 
are growing calls for patients with IBD to be monitored for mood disorders (Gracie et al., 
2018). Psychological treatment is not currently part of usual care in IBD treatment. This may 
be because there are typically only modest or short-term gains, when the IBD populations is 
considered (Gracie et al., 2017). However, there is a growing awareness that there are groups 
who, when targeted, may strongly benefit (Gracie et al., 2017; Mikocka-Walus et al., 2015). 
There is, however, a theoretical model which may assist in identifying a subset of people 
who may benefit from psychological intervention: the theory of subjective wellbeing 
homeostasis (Homeostasis Theory). 
 
1.2  Subjective wellbeing homeostasis 
Homeostasis Theory was developed to explain constancy in reported levels of SWB across 
time and populations (Cummins, 1995; Cummins et al., 2018; Cummins et al., 2014; Davern 
et al., 2007). It proposes that SWB operates as an internal psychological system using 
homeostatic mechanisms, which maintain SWB within an individual set-point range, even in 
the face of psychological stressors. It is only when these stressors become overwhelming, and 
homeostasis is defeated, that chronic psychological consequences emerge (Lyall et al., 2021). 
The theory proposes that there is, for each person, a set-point for a mood-derived positive-
activated affect called Homeostatically Protected Mood (HPMood), and that this underlying 
mood governs subjective levels of wellbeing (Capic et al., 2017). The level of this set-point is 
genetically determined and constant. Moreover, the maintenance of this level is supported by 
a homeostatic system that strives to maintain experienced levels of HPMood within each 
individual’s set-point range (Cummins, 2016). According to the theory, stressors challenge 
homeostatic control, by shifting conscious awareness of affect to the situationally created 
emotion, rather than the underlying HPMood. If the challenge is strong and chronic, 
homeostatic control fails, and the consequence is persistent negative affect, and depression 









1.3  Measuring HPMood and homeostatic defeat 
Measuring HPMood, and homeostatic defeat, requires the ability to separate out the 
emotional content of responses to affect-related questions, from the underlying HPMood. This 
has been demonstrated by a processes that examines the within-person standard deviation of 
SWB scores over time, demonstrated first by Cummins et al. (2014); and then Capic et al. 
(2017). Individuals who are experiencing homeostatic failure will have a higher level of 
emotional content, arising from stress, and this emotional content will dominate their 
underlying HPMood and mask their responses to either questions of SWB, or the questions 
used to elicit HPMood (happy, content, alert). Thus, the individual will have much larger 
variations of those reported measures over time.  
A substantial empirical literature supports Homeostatic Theory (see Cummins, 2017, for a 
summary). Clinical benefits of this theory are that individuals who are experiencing mood 
homeostasis defeat can be targeted to identify appropriate treatment. However, there has been 
little research into how the theory may be effectively translated into clinical programs or 
interventions. Specifically, this theorised relationship has not been empirically tested using a 
randomised control trial (RCT) with a population known to be a risk of psychological distress. 
This study aims to explore this research gap by focussing on an intervention that has been 
proposed to have similar mechanisms to mood homeostasis: mindfulness (Lyall et al., 2021) . 
 
1.4  Mindfulness  
Mindfulness first came to the attention of western psychologists in the 1970s with the 
development of Mindfulness Based Stress Reduction (Kabat-Zinn, 2013). There are many 
approaches and definitions of mindfulness, but a common thread is that mindfulness introduces 
“a space between one’s perception and response” (Bishop et al., 2004, p. 232). The outcome 
of mindfulness has been described as equanimity, defined as “an even-minded mental state or 
dispositional tendency toward all experiences or objects, regardless of their affective valence 
… or source” (Desbordes et al., 2015, p. 4). This description is analogous to a conscious 
awareness of HPMood. If stress precipitates failure of SWB homeostasis, the alleviation of 
stress should assist the restoration of homeostasis; leading to improvements in both mood and 
disease symptoms (Lyall et al., 2021).  
Few studies have explored the impact of mindfulness on wellbeing in patients with 
inflammatory bowel disease, and even fewer have focused on the disease of interest in this 
study, CD, or on the intervention of interest, Mindfulness Based Stress Reduction (MBSR). 
One study, involving 60 inflammatory bowel disease patients (44 with CD) compared a 
mindfulness-based intervention with a treatment-as-usual control and found significantly 
greater improvements in depression at the six-month follow up. Impact on disease symptoms 
was not measured (Neilson et al., 2015). A pilot RCT involving 44 patients investigated the 
feasibility of conducting a larger mindfulness-based cognitive therapy RCT (Schoultz et al., 
2015). Their exploratory findings found a significant improvement in scores for depression for 
the intervention group compared to the wait-list control.  
Emerging evidence that MSBR interventions may be effective for both psychological and 
physiological stress comes from a randomised experimental study with 49 healthy participants 
(Rosenkranz et al., 2013). Both psychological and physiological stress were induced, 
separately, to participants before and after their training (MBSR or active education-based 
control) programs. Results showed both groups had comparable post-training cortisol 
responses; however, the MSBR group had a significantly smaller post-stress inflammatory 
response despite the similar levels of stress hormones.  
It is not known if mindfulness can reduce inflammatory markers of IBD. One small 
randomized control trial involving 29 IBD patients explored the effectiveness of breathing, 
 




movement and meditation and involved (Gerbarg et al., 2015). The treatment group had 
significant improvements in psychological measures (anxiety, depression and stress) as well as 
disease measures (C-reactive protein, a marker of disease activity) at the six-month follow-up. 
The intervention, however, was a collection of techniques, mostly based on the martial art of 
Qigong, making replication difficult. 
Many previous IBD studies have recruited patients with either ulcerative colitis or CD, 
reducing the size of the sample in each disease category. This approach has been critiqued as 
creating dilution effects (Cámara et al., 2009), with a recommendation that future studies 
consider each condition separately. To the authors’ knowledge there has been no study of the 
impact of MBSR training on objective inflammatory markers of CD such as C-reactive protein 
levels (CRP).  
If MBSR is found to improve disease activity in patients with CD, while simultaneously 
restoring mood homeostasis, it would provide further support for interventions that target 
psychological stress reduction to improve physiological outcomes.  
 
1.5  Study objectives 
The overarching aim of the study is to explore the relationship between HPMood, stress, 
inflammation, and depression in a sample of patients with CD.  
Specifically, the study aims to explore whether mindfulness training can: 
1) Reduce symptoms of stress following the MBSR course as compared to standard 
care and to investigate whether this is sustained at 6 month follow up,  
2) Reduce symptoms of depression following the MBSR course as compared to 
standard care and to investigate whether this is sustained at 6 month follow up  
3) Reduce inflammation following the MBSR course as compared to standard care and 
to investigate whether this is sustained at 6 month follow up.  
4) Reduce the fluctuation of emotional content in participants’ experience of their 
underlying mood following the MBSR course as compared standard care and to 
investigate whether this is sustained at 6 month follow up.  
 
1.6  Hypotheses 
That, prior to the MBSR intervention, levels of perceived stress, depression, CRP and 
HPMood variance will not differ between the intervention and usual care control groups.  
That, following the intervention, levels of perceived stress, depression, CRP and HPMood 
variance will decrease for the intervention, but not for the usual care control groups. 
That the effectiveness of the intervention can be predicted from the baseline levels of 
HPMood, such that only participants whose baseline levels show evidence of homeostatic 
defeat would be predicted to achieve homeostasis as a result of the intervention. 
 
2.  Methods/Design 
2.1 Design  
An exploratory randomised single-blind controlled trial, with a sample of approximately 40 
CD patients, with 20 forming the mindfulness group and 20 participating in a wait-list 
control/treatment as usual (Figure 1). Patients will be randomly assigned to either group A 
(mindfulness) or group B (waitlist/usual care) using a computer-generated block randomisation 
by a statistician with no patient contact. The intervention group will participate in an 8-week 












2.2  Participants 
Participants will be CD patients currently receiving treatment at public gastroenterology 
practices in Victoria (e.g., Barwon Health Gastroenterology).  
 
Inclusion Criteria  
1) A clinically established diagnosis of Crohn’s disease (per usual clinical practice in a 
tertiary care centre) 
2) Sufficient knowledge of English to understand the study instructions, answer the 
questionnaires and participate in the MBSR group.  
3) 18 years of age or older 
4) Competence to consent 
5) Access to the internet by a smart phone and the willingness to download the Instant 
Survey app.  
6) A willingness to commit to 2.5 hours of MBSR at the identified times for a period of 8 
consecutive or near-consecutive weeks, and engage with the homework sheets in the 
intervening period. 
7) Scores of depressive symptoms at mild or moderate levels of the DASS scale 
 
Exclusion Criteria  
1) Alcohol/substance dependence, as identified by the gastroenterology team 
2) Severe mental illness (e.g., psychosis, schizophrenia), as identified by the 
gastroenterology team 
3) Severe anxiety or depressive symptoms as indicated by a scores >21 on the depression 
scale or > 15 on the anxiety scale of the DASS measure   
4) Significant cognitive impairment 
5) Inability to read or write 
6) Inability to speak or understand English  
7) A regular (weekly or more often) mindfulness practice. 
 
 





Participants will be free to withdraw at any time without any aspect of their IBD care being 
affected by their decision to withdraw from the study. 
 
2.3  Recruitment 
Potentially eligible patients will be identified by the IBD nurse and/or gastroenterologists 
and contacted in person, via letter, or email and invited to participate. The study objectives 
and procedure will be outlined in an initial conversation between the study investigators and 
potential participant. The potential participant will be provided with the participant 
information and consent form. Participants will be assured their participation is voluntary and 
will not impact their treatment.  
 
2.4  Intervention and control condition 
The MBSR intervention will be delivered following the procedure on the Palouse 
Mindfulness training course, as shown in Table 1. Each week consists of a 2.5 hour group 
session and up to 45 minutes of daily mindfulness practice using homework exercises. The 
group sessions involve a combination of watching videos explaining various mindfulness 
techniques, practicing those techniques and group discussion. Homework sessions will involve 
daily practice of the techniques learned.  
The waitlist control group will be provided with the opportunity to complete the same 
MBSR course, following the completion of the 6-month follow-up period. In the event that the 
intervention is of no benefit or produces some undesired effects it will not be offered to the 
control group. However, the control group will then receive information on other free evidence-
based tools for self-care, e.g., www.tameyourgut.com. 
 
Table 1.  Session Structure of the MBSR program 
 
Week Content Format/materials Homework tasks 
1 “Simple 
Awareness” 
Introduction to the 
body scan 
Videos, and introductory 
reading, participation in 30 




2 “Attention and the 
brain”  
Introduction to sitting 
meditation 
Videos, formal sitting 
meditation practice (10 
minutes), group discussion 
Reading, practice 
sheets 
3 “Dealing with 
Thoughts”  
Introduction to yoga  Videos, formal introduction 
to yoga practice (30 






Stop: the one-minute 
breathing space 
Videos, formal introduction 




5 “Dealing with 
Difficult emotions 
or physical pain” 
Turning toward  Videos, the Turning 









6 “Mindfulness and 
Communication” 
Mountain and Lake 
meditations 
Videos, Mountain and Lake 
meditation, communication 
calendar, group discussion. 
Reading, practice 
sheets 









8 “Conclusion” Developing a practice 
of your own  




As part of the introduction in the first session of the course, participants will be informed 
about the possibility that some aspects of mindfulness practice could result in some distress 
and recommended actions to take should this occur. This information will also be prominently 
feature in the participant manual.  
 
2.5  Measures   
Subjective Wellbeing (SWB) will be measured with the Personal Wellbeing Index 
(International Wellbeing Group, 2013). HPMood will be measured by three items: right now, 
how happy do you feel, right now, how content do you feel, right now, how alert do you feel 
(Davern et al., 2007). Symptoms of depression and stress will be measured through the relevant 
sub-scales of the Depression, Anxiety and Stress Scale (Lovibond & Lovibond, 1995). 
Inflammation will be measured through c-reactive protein levels.  
 
2.6  Procedure  
At T1, participants will be prompted, via a smartphone app known as Instant Survey, to 
answer a short series of questions relating to their HPMood. These will include the 3 HPMood 
variables, along with additional questions, “how depressed do you feel” and “how stressed do 
you feel”. They will be prompted to answer these questions up to 7 times per day for 7 days. 
Each questionnaire will take approximately 30 seconds to complete. At the end of the 1-week 
period, participants will be asked a series of general questions about their SWB, depression 
and stress, once only and also via the smart-phone app. These questions will take approximately 
15 minutes to complete. Following the completion of these initial surveys, participants in the 
intervention group will be provided with the 8-week MBSR intervention; while those in the 
wait-list will be provided with usual treatment, including anti-inflammatory medication if 
indicated. At completion of the MBSR course, the 1-week moment sampling questions and the 
longer survey will be repeated; along with an evaluation of the MSBR course. Participants will 
also be asked to provide a log of their homework practice. Participants will then be asked to 
participate in a follow-up 6 months later, which will repeat the 1-week moment sample and 
longer surveys. Participants in the control group will be provided with the surveys eight weeks 
after they completed them in T1. 
 
2.7  Data analysis 
Analysis of quantitative data 
Given the exploratory nature of this pilot RCT, no a priori power analysis was conducted. 
The sample size of 40 was chosen as being an achievable size for the study’s resources, and 
will allow up to four MBSR groups, each containing 10 participants.  
 
 




Data analyses conducted for the hypotheses are as follows:  
 
Analyses: For all outcome variables (stress, depression, SWB and CRP levels, HPMood 
variance), mixed ANOVA (with both between-subjects and within subject factors) analyses 
will be conducted to compare the results for the intervention and control groups. For mood 
homeostasis, the outcome measure is the level of within-person variance, calculated by 
analysing each individual’s scores contributed over the one-week period (Capic et al., 2017).  
To account for the likely lack of power, data from the intervention group will also be 
analysed using clinical significance testing to identify whether their scores are closer to known 
normative data or to known pathological levels (Jacobson & Truax, 1991). Normative range 
for each outcome measure will be sourced as follows: For SWB and HPMood: Capic et al. 
(2017); for depression and stress, the DASS severity scales; for CRP levels, based on 
Australian Clinical Laboratories reference range.  
For the intervention group, analyses for the six-month follow-up will control for whether 
the individual is continuing to engage in regular mindfulness practice. This will be assessed 
via self-report, by asking participants to report how often they continue to engage in 
mindfulness practice.  
 
3. Discussion 
The psychological cost of Crohn’s disease (CD) is high. Given the prevalence of the disease 
in Australia, and the high levels of psychological symptoms associated with the condition, it is 
important that potential treatments that might help to improve both psychological and 
physiological outcomes are explored (Häuser et al., 2014; Lores et al., 2021). While many IBD 
patients are increasingly exploring the use of non-traditional psychological treatments such as 
mindfulness, more research is needed to identify the specific benefits on both disease activity 
and psychological symptoms (Torres et al., 2019). More broadly, there is a growing call for 
research that more comprehensively understands the environmental triggers associated with 
IBD (Ho et al., 2019), and in particular to do this with longitudinal research that can provide 
insight into causal relationships. In addition, studies that identify the role of resilience in 
combatting the psychological and physiological symptoms associated with IBD are needed, 
building on emerging evidence of resilience protecting wellbeing in IBD patients (Sehgal et 
al., 2021; Wang et al., 2021). 
Our proposed study can contribute to these known research gaps. The study has been framed 
within a clear theoretical context, outlining the likely relationship between stress, mood, 
depression, and inflammation. This pilot trial has the potential to contribute to further research 
in three ways. First, its randomised control design will allow between-group comparisons that 
will provide pilot data for subsequent effectiveness studies. Second, data from the participants 
can be analysed on an individual basis to determine whether progress made was clinically 
significant. Third, the ability to identify whether individuals are in HPMood homeostatic defeat 
could help to identify likely targets of people who could benefit from MBSR interventions. 
There are some limitations with our proposed study. The small sample size would mean that 
the results can be considered indicative only; however, they will add to the growing literature 
and provide useful guidance for larger, future studies. Our focus on CD patients would mean 
results could not be generalised to other populations with IBD; however this is also a strength 
as it supports calls to research interventions with each IBD disease cohort separately (Cámara 
et al., 2009) and also responds to evidence that people with CD have more psychological 
complaints than those with another common subtype of IBD, ulcerative colitis (Mikocka-
Walus, Knowles, et al., 2016; von Wietersheim & Kessler, 2006). Another potential limitation 
could emerge should coronavirus-19 pandemic continue and result in restrictions preventing 
 




group work. Given the MBSR protocol involves weekly group sessions, it will be important to 
consider the impact on the study should an on-line alternative need to be developed.  
Strengths of the proposed study are the RCT design, and the collection of inflammatory 
markers as well as subjective symptoms. Recruitment through the gastroenterology unit is also 
likely to include a wide cohort of patients experiencing both active and inactive disease, 
responding to a known challenge in prior studies that more commonly involve only patients 
with inactive or mild disease symptoms (Knowles et al., 2013). Finally, the ability to determine 
the clinical significance of any improvement of each individual participant, which can provide 
direct guidance for future research as well as inform clinical decisions, is the study’s clear 
strength.   
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